Upadacitinib
APICAS: 1310726-60-3
Sample Stock:
Upadacitinib is an oral, targeted medication used to treat several moderate-to-severe autoimmune and inflammatory conditions. It belongs to a class of drugs called JAK inhibitors and is specifically designed to selectively target the JAK1 enzyme, a key driver of inflammation.
Related Information
Purity:98%+
Registration:GMP/DMF
Biological Profile
Biological Targets
JAK1·JAK2·JAK3·TYK2
Associated Conditions
atopic eczema·psoriatic arthritis·immune system disease·Crohn's disease·hidradenitis suppurativa·
Key Intermediates
3 Items| Structure | Name | CAS No. | Sample Stock | MDL No. | Details |
|---|---|---|---|---|---|
 | benzyl (3R,4S)-3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate | 1428243-26-8 | MFCD30802183 | ||
 | 1,1-Dimethylethyl N-(5-((4-methylphenyl)sulfonyl)-5H-pyrrolo(2,3-b)pyrazin-2-yl)carbamate | 1201187-44-1 | MFCD28129728 | ||
 | 8-((3R,4S)-4-Ethylpyrrolidin-3-yl)-3-tosyl-3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazine | 1428243-28-0 | - |